194 related articles for article (PubMed ID: 19576866)
1. Inhibitory mechanisms of heterocyclic carboxaldehyde thiosemicabazones for two forms of human ribonucleotide reductase.
Zhu L; Zhou B; Chen X; Jiang H; Shao J; Yen Y
Biochem Pharmacol; 2009 Nov; 78(9):1178-85. PubMed ID: 19576866
[TBL] [Abstract][Full Text] [Related]
2. Determination of the potency and subunit-selectivity of ribonucleotide reductase inhibitors with a recombinant-holoenzyme-based in vitro assay.
Shao J; Zhou B; Zhu L; Bilio AJ; Su L; Yuan YC; Ren S; Lien EJ; Shih J; Yen Y
Biochem Pharmacol; 2005 Feb; 69(4):627-34. PubMed ID: 15670581
[TBL] [Abstract][Full Text] [Related]
3. 2,2'-Bipyridyl-6-carbothioamide and its ferrous complex: their in vitro antitumoral activity related to the inhibition of ribonucleotide reductase R2 subunit.
Nocentini G; Federici F; Franchetti P; Barzi A
Cancer Res; 1993 Jan; 53(1):19-26. PubMed ID: 8416745
[TBL] [Abstract][Full Text] [Related]
4. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs.
Li J; Zheng LM; King I; Doyle TW; Chen SH
Curr Med Chem; 2001 Feb; 8(2):121-33. PubMed ID: 11172670
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone).
Barker CA; Burgan WE; Carter DJ; Cerna D; Gius D; Hollingshead MG; Camphausen K; Tofilon PJ
Clin Cancer Res; 2006 May; 12(9):2912-8. PubMed ID: 16675588
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and ribonucleotide reductase inhibitory activity of thiosemicarbazones.
Krishnan K; Prathiba K; Jayaprakash V; Basu A; Mishra N; Zhou B; Hu S; Yen Y
Bioorg Med Chem Lett; 2008 Dec; 18(23):6248-50. PubMed ID: 18976907
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of drug resistance involving ribonucleotide reductase: hydroxyurea resistance in a series of clonally related mouse cell lines selected in the presence of increasing drug concentrations.
Choy BK; McClarty GA; Chan AK; Thelander L; Wright JA
Cancer Res; 1988 Apr; 48(8):2029-35. PubMed ID: 2832057
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells.
Zhou BS; Hsu NY; Pan BC; Doroshow JH; Yen Y
Cancer Res; 1995 Mar; 55(6):1328-33. PubMed ID: 7882331
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones.
Cory JG; Cory AH; Rappa G; Lorico A; Liu MC; Lin TS; Sartorelli AC
Biochem Pharmacol; 1994 Jul; 48(2):335-44. PubMed ID: 8053929
[TBL] [Abstract][Full Text] [Related]
10. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
Cory AH; Sato A; Thompson DP; Cory JG
Oncol Res; 1996; 8(10-11):449-56. PubMed ID: 9114437
[TBL] [Abstract][Full Text] [Related]
11. The potent and novel thiosemicarbazone chelators di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone and 2-benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone affect crucial thiol systems required for ribonucleotide reductase activity.
Yu Y; Suryo Rahmanto Y; Hawkins CL; Richardson DR
Mol Pharmacol; 2011 Jun; 79(6):921-31. PubMed ID: 21389104
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase.
Green DA; Antholine WE; Wong SJ; Richardson DR; Chitambar CR
Clin Cancer Res; 2001 Nov; 7(11):3574-9. PubMed ID: 11705879
[TBL] [Abstract][Full Text] [Related]
13. Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
Tsimberidou AM; Alvarado Y; Giles FJ
Expert Rev Anticancer Ther; 2002 Aug; 2(4):437-48. PubMed ID: 12647987
[TBL] [Abstract][Full Text] [Related]
14. In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase.
Shao J; Zhou B; Zhu L; Qiu W; Yuan YC; Xi B; Yen Y
Cancer Res; 2004 Jan; 64(1):1-6. PubMed ID: 14729598
[TBL] [Abstract][Full Text] [Related]
15. A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase.
Shao J; Zhou B; Di Bilio AJ; Zhu L; Wang T; Qi C; Shih J; Yen Y
Mol Cancer Ther; 2006 Mar; 5(3):586-92. PubMed ID: 16546972
[TBL] [Abstract][Full Text] [Related]
16. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.
Finch RA; Liu M; Grill SP; Rose WC; Loomis R; Vasquez KM; Cheng Y; Sartorelli AC
Biochem Pharmacol; 2000 Apr; 59(8):983-91. PubMed ID: 10692563
[TBL] [Abstract][Full Text] [Related]
17. Redox property of ribonucleotide reductase small subunit M2 and p53R2.
Liu X; Xue L; Yen Y
Methods Mol Biol; 2008; 477():195-206. PubMed ID: 19082948
[TBL] [Abstract][Full Text] [Related]
18. Circular dichroism and magnetic circular dichroism studies of the active site of p53R2 from human and mouse: iron binding and nature of the biferrous site relative to other ribonucleotide reductases.
Wei PP; Tomter AB; Røhr AK; Andersson KK; Solomon EI
Biochemistry; 2006 Nov; 45(47):14043-51. PubMed ID: 17115699
[TBL] [Abstract][Full Text] [Related]
19. Ribonucleotide reductase inhibition by metal complexes of Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone): a combined experimental and theoretical study.
Popović-Bijelić A; Kowol CR; Lind ME; Luo J; Himo F; Enyedy EA; Arion VB; Gräslund A
J Inorg Biochem; 2011 Nov; 105(11):1422-31. PubMed ID: 21955844
[TBL] [Abstract][Full Text] [Related]
20. Structurally dependent redox property of ribonucleotide reductase subunit p53R2.
Xue L; Zhou B; Liu X; Wang T; Shih J; Qi C; Heung Y; Yen Y
Cancer Res; 2006 Feb; 66(4):1900-5. PubMed ID: 16488986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
